| Market Cap | 22.85M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -31.57M | Forward P/E | -0.61 | EPS next Y | - | 50D Avg Chg | -15.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -37.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -67.00% |
| Recommedations | 2.00 | Quick Ratio | 0.52 | Shares Outstanding | 54.52M | 52W Low Chg | 26.00% |
| Insider Own | 48.23% | ROA | -95.05% | Shares Float | 24.48M | Beta | 1.91 |
| Inst Own | 0.01% | ROE | - | Shares Shorted/Prior | 2.13M/0.96M | Price | 0.72 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 926,735 | Target Price | - |
| Oper. Margin | - | Earnings Date | Oct 2 | Volume | 657,961 | Change | -0.01% |
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PERRY DAVID P | Executive Chairman Executive Chairman | Jul 27 | Buy | 0.7299 | 1,233,045 | 900,000 | 13,030,393 | 07/31/23 |
| Berman Mark A. | Chief Medical Office.. Chief Medical Officer | Jul 27 | Buy | 0.7299 | 54,802 | 40,000 | 388,191 | 07/31/23 |
| Armanino Andrew J. | Director Director | Jul 27 | Buy | 0.7299 | 274,010 | 200,000 | 728,368 | 07/31/23 |
| Granger Elder | Director Director | Jul 27 | Buy | 0.7299 | 34,251 | 25,000 | 35,851 | 07/31/23 |
| KARBE FRANK | Chief Executive Offi.. Chief Executive Officer | Jul 27 | Buy | 0.7299 | 137,005 | 100,000 | 429,429 | 07/31/23 |
| Parker Geoffrey M. | Director Director | Jul 27 | Buy | 0.7299 | 685,025 | 500,000 | 1,028,055 | 07/31/23 |
| Granger Elder | Director Director | May 16 | Buy | 0.8672 | 600 | 520 | 1,600 | 05/18/23 |
| PERRY DAVID P | See Remarks See Remarks | Apr 10 | Buy | 0.83 | 4,969,697 | 4,124,849 | 3,636,364 | 04/12/23 |
| PERRY DAVID P | See Remarks See Remarks | Sep 15 | Buy | 2.03 | 50,000 | 101,500 | 101,536 | 09/19/22 |
| KARBE FRANK | See Remarks See Remarks | Sep 15 | Buy | 2.0939 | 50,000 | 104,695 | 50,000 | 09/15/22 |
| Armanino Andrew J. | Director Director | Jun 14 | Buy | 1.3897 | 15,000 | 20,846 | 15,000 | 06/16/22 |
| Heinen Mark | See Remarks See Remarks | Jun 10 | Buy | 1.56 | 5,000 | 7,800 | 20,000 | 06/10/22 |
| Zamirowski Justin | Chief Commercial Off.. Chief Commercial Officer | May 16 | Option | 0.50 | 35,236 | 17,618 | 35,236 | 05/18/22 |
| Armanino Andrew J. | Director Director | Mar 29 | Buy | 2.1405 | 40,000 | 85,620 | 126,328 | 03/31/22 |
| Parker Geoffrey M. | Director Director | Mar 29 | Buy | 2.1487 | 15,000 | 32,230 | 15,000 | 03/31/22 |